top stories

Which drug de­vel­op­ers of­fer Trump a quick, game-chang­ing ‘so­lu­tion’ as the pan­dem­ic roars back? Eli Lil­ly and Ab­Cellera look to break out of the pack

6 hours ago
Pharma
Coronavirus

Look­ing for 'ex­ter­nal in­no­va­tion,' Boehringer In­gel­heim re­serves $500M+ for new Shang­hai hub

3 days ago
China

No­var­tis pays $678M for kick­back scheme as Vas Narasimhan tries to dis­tance phar­ma gi­ant from shady be­hav­ior

3 days ago
Pharma

Latest

Most read

Tes­la chief Elon Musk teams up with Covid-19 play­er Cure­Vac to build 'R­NA mi­cro­fac­to­ries'

3 days ago
People
Coronavirus

Bio­gen bags an AAV gene ther­a­py pro­gram from Mass­a­chu­setts Eye and Ear; Biotechs raised $1B-plus in lat­est round of ...

3 days ago
Protocols

No­vavax snags Ben Machielse for CMC and pro­motes a trio of staffers; Mar­ty Du­vall lands an­oth­er CEO post at ...

3 days ago
Peer Review

De­vel­op­ment part­ners at MEI, Helsinn dump a high-risk PhI­II AML study af­ter con­clud­ing it would fail sur­vival goal

3 days ago
R&D
see latest stream
People

UP­DAT­ED: Re­gen­eron co-founder George Yan­copou­los of­fers a com­bat­ive de­fense of the po­lice at a high school ...

4 days ago

Elias Zer­houni dis­cuss­es ‘am­a­teur hour’ in DC, the de­struc­tion of in­fec­tious dis­ease R&D and how we need to prep ...

5 days ago

EMA nom­i­nates Emer Cooke as ex­ec­u­tive di­rec­tor to re­place Gui­do Rasi

Last week
Startups

Out of jobs, a pair of ear­ly cell ther­a­py ex­ec­u­tives went to Seoul, came back with a new com­pa­ny, $70M and a plan to ...

Last week

Yale spin­out re-en­gi­neers an im­munother­a­py GSK, oth­ers once aban­doned

Last week

A vir­tu­al biotech in­cu­ba­tor is launch­ing with the help of Evotec and Sam­sara, look­ing for a few good sci­en­tists in ...

Last week
Deals

An ex­pe­ri­enced biotech is stitched to­geth­er from transpa­cif­ic parts, with 265 staffers and a fo­cus on ‘new ...

4 days ago

Back to the im­munol­o­gy draw­ing board, Ab­b­Vie inks dis­cov­ery deal with old Al­ler­gan part­ner

Last week

In an un­ex­pect­ed twist, CSL buys world­wide rights to uniQure's PhI­II he­mo­phil­ia B gene ther­a­py in $2B-plus deal

Last week
IPOs

Free­line nabs $120M, eyes IPO as its gene ther­a­py comes in­to fo­cus

5 days ago

The biotech IPO boom is be­com­ing ‘his­toric’ as four more throw their hats in

6 days ago

No­var­tis-backed Po­sei­da is pack­ing in the cash for its next-gen CAR-T work, adding a $110M ven­ture raise on top of ...

Last week

Premium storiesSee all

Day one: The dis­rup­tor-in-chief at Bridge­Bio in­vites Brent Saun­ders on­to the board

Last week
People
Bioregnum

What’s it take to raise $700M-plus for a biotech start­up? Steve Harr has some thoughts on that

Last week
Venture
Cell/Gene Tx

Two Bay Area up­starts out to de­liv­er on cell ther­a­py 2.0 join forces on a quest: pur­su­ing a Holy Grail in on­col­o­gy ...

3 weeks ago
Deals
Cell/Gene Tx

The FDA backs off a hasty — and dam­ag­ing — emer­gency OK for a po­ten­tial­ly dan­ger­ous Covid-19 drug

3 weeks ago
Bioregnum
R&D

Don't missSee all

IPO bound? A Bay Area biotech grabs a mega-round on the road to a piv­otal neu­rode­gen­er­a­tion pro­gram

3 days ago
Venture

Pfiz­er shares surge on pos­i­tive im­pact of their mR­NA Covid-19 vac­cine — part­nered with BioN­Tech — in an ...

4 days ago
R&D
Coronavirus

Covid-19 roundup: Vac­cines will need to beat place­bo by 50% to qual­i­fy for FDA OK; UK tri­al drops Kale­tra

5 days ago
Coronavirus

Take­da maps out a dis­cov­ery al­liance aimed at break­ing through the safe­ty and ef­fi­ca­cy bound­aries that lim­it the ...

5 days ago
Venture
R&D

Endpoints Standouts

The 20 un­der 40: In­side the next gen­er­a­tion of bio­phar­ma lead­ers

3 months ago
People
Special

Here are the 52 new drugs ap­proved by the FDA in 2019. Who won? Who lost? And who just sur­vived to 2020?

6 months ago
Special
Pharma

Spe­cial re­port: Twen­ty ex­tra­or­di­nary women in bio­phar­ma R&D who worked their way to the top

7 months ago
People
R&D

[Video] Cel­e­brat­ing tri­al fail­ures, chang­ing the cul­ture and al­ly­ing with Cal­i­for­nia dream­ers: R&D chief Hal Bar­ron ...

8 months ago

Peer review See all

Jun
26

In­ovio adds two to the lead­er­ship team; Adri­an Woolf­son is out at Sang­amo

Jun
19

Boehringer In­gel­heim nabs new US pres­i­dent and CEO; As­traZeneca vet hops aboard No­vavax as CMO

Jun
12

'Ris­ing star' CEO re­counts path from pre-med to break­through meds; Den­dreon taps Big Phar­ma vet Ja­son O'Neill as CEO

Jun
5

David Chang steps up to CEO spot at WuX­i's cell and gene ther­a­py CD­MO; David Meline is the new CFO at Mod­er­na

May
29

Sier­ra On­col­o­gy brings on for­mer Aim­mune CEO to the helm; Flag­ship woos ex-No­var­tis ex­ec Fab­rice Chouraqui

R&D channel feed

4 days ago

Io­n­is, lead­ing MS re­searcher throw an­ti­sense at a new type of brain cells

No mat­ter how many mol­e­cules he threw at them, Paul Tesar couldn’t get the brain cells to sur­vive. Or he got them to sur­vive, but then — to every­one’s baf­fle­ment — they still ...

READ MORE

Bolt Bio­ther­a­peu­tics nabs $93.5M to push Provenge in­ven­tor's new idea deep­er in the clin­ic

4 days ago
Venture

Days af­ter In­ter­cept re­jec­tion, Akero surges on ‘un­prece­dent­ed‘ NASH da­ta

4 days ago
latest in R&D

Covid-19 has roiled clin­i­cal tri­al plans around the world, rais­ing con­cerns over the in­dus­try’s fu­ture on new drug ap­provals

4 days ago
Coronavirus

Zyner­ba flunks an­oth­er ma­jor tri­al, all but end­ing Frag­ile X hopes

5 days ago

Pos­i­tive Covid-19 vac­cine da­ta? New mouse study? OWS in­clu­sion? Yep, but some­how, the usu­al tid­bits from In­ovio back­fire

5 days ago
Bioregnum

Seat­tle Ge­net­ics, Gen­mab turn on TV for a high­light reel in cer­vi­cal can­cer — but a ri­val biotech promis­es a bet­ter show

5 days ago

FDA re­jects In­ter­cept’s pitch for NASH as CEO fires back at the agency’s ‘evolv­ing’ guide­lines

6 days ago
Regulatory
see latest stories

Pharma channel feed

4 days ago

New stan­dard of care? FDA hands Pfiz­er, Mer­ck KGaA an OK for Baven­cio in blad­der can­cer

The break­through ther­a­py des­ig­na­tion Pfiz­er and Mer­ck KGaA notched for Baven­cio in blad­der can­cer has quick­ly paved way for a full ap­proval. The PD-L1 drug is now sanc­tioned as ...

READ MORE

No­var­tis los­es biosim­i­lar ap­peal as court up­holds a 31-year mo­nop­oly by Am­gen's En­brel

3 days ago
Regulatory

On a roll, Mer­ck blazes through a new seg­ment of the bio­mark­er trail

5 days ago
Regulatory
latest in Pharma

Take­da takes a $200M hit af­ter No­var­tis is forced to yank its mar­ket­ing ap­pli­ca­tion for Xi­idra

6 days ago
Regulatory

Gilead opts for $3,120 US in­sur­er price for Covid-19 drug remde­sivir — but some say it should be free

6 days ago

DBV lays off em­ploy­ees, scales down pro­grams af­ter re­ceiv­ing no word from FDA

Last week
Regulatory

Sanofi preps an­oth­er round of lay­offs as new ex­ecs look to slim down the glob­al phar­ma in an on­go­ing re­or­ga­ni­za­tion — re­port

Last week

Af­ter 2 de­lays, Zo­genix nabs FDA ap­proval for epilep­sy drug, sets price at 3X its GW Phar­ma com­peti­tor

Last week
Regulatory
see latest stories

Coronavirus channel feed

5 days ago

WHO ACT-Ac­cel­er­a­tor pri­or­i­tizes glob­al vac­cine ap­proach

The im­por­tance of a glob­al ap­proach to vac­cine de­vel­op­ment and pro­duc­tion, with a fo­cus on col­lab­o­ra­tion, was a top­ic of a tech­ni­cal up­date and press brief­ing held 26 June by the ...

READ MORE

Covid-19 roundup: Temasek leads a $250M raise for BioN­Tech as first Covid-19 mR­NA vac­cine da­ta looms; Chi­na's ...

6 days ago

Covid-19 roundup: Mod­er­na en­lists Catal­ent as man­u­fac­tur­ing part­ner, se­cur­ing fill-fin­ish ca­pac­i­ty for the first 100M ...

Last week
latest in Coronavirus

Covid-19 roundup: An­tho­ny Fau­ci, Stephen Hahn tes­ti­fy in Con­gress; Chi­na's Sinopharm speeds in­to PhI­II vac­cine tri­al

Last week

Hahn tes­ti­fies on Covid-19 re­sponse, says FDA on tar­get to hit user fee goals

Last week
Regulatory

Law­mak­ers ask FDA to out­line Covid-19 vac­cine ap­proval process

Last week
Regulatory

Covid-19 roundup: $71M from DoD to In­ovio; Pigs pro­vide clues on Ox­ford vac­cine; Google lends su­per­com­put­ing to an­tivi­ral hunt

Last week

Covid-19 roundup: In fifth open let­ter, Daniel O’Day touts in­halant remde­sivir, promis­es 2M dos­es by year's end; Mer­ck’s an­tivi­ral moves in­to PhII

2 weeks ago
see latest stories